Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

NCT03386513 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03386513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03386513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 2, 2018
Completion date
December 30, 2026
Enrollment
179 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasm